Pediatric Nephrology

, Volume 33, Issue 1, pp 111–116 | Cite as

Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis

  • Julien HoganEmail author
  • Astrid Godron
  • Véronique Baudouin
  • Theresa Kwon
  • Jérôme Harambat
  • Georges Deschênes
  • Olivier Niel
Original Article



In clinical trials, the addition of rituximab (RTX) to the combination therapeutic regimen of mycophenolate mofetil (MMF) and corticosteroids failed to improve outcome in lupus nephritis (LN). However, recent data suggest that RTX may have steroid-sparing beneficial effects with an efficacy similar to that of conventional regimens. We report our experience with RTX in the treatment of children with LN.


Patients treated with RTX for first occurrence of LN class III to V were enrolled in the study. Treatment consisted of methylprednisolone pulse (500 mg/m2) followed by RTX (1000 mg/1.73 m2) at days 1 and 15, and MMF (1200 mg/m2/day). Prednisolone tapering and withdrawal was left to the physician’s discretion. Complete remission (CR) was defined as a urine protein-to-creatinine ratio (U Pr/Cr) of <5 mg/mg and normal serum creatinine, and partial remission (PR) as a U Pr/Cr of <30 mg/mg and a <15% rise in serum creatinine over baseline.


Twelve patients were included in the study, with median follow-up of 23.7 [interquartile range (IQR) 12.8–33.5] months. Median age of the patients was 13.6 [12.3–15.1] years, median proteinuria was 32 [19–67] mg/mg and median estimated glomerular filtration rate was 76.1 [59.3–97.7] mL/min/1.73 m2. Median CD20 depletion duration was 10 [6.8–11.0] months. Prednisolone was rapidly tapered, with median dose of 0.3 [0.15–0.41], 0.10 [0.09–0.16] and 0.0 [0.0–0.04] mg/kg/day at 3, 6 and 12 months respectively. At 3 months, three and seven patients achieved CR and PR, respectively; at 6 and 12 months all patients achieved remission (9 CR, 3 PR) and none relapsed during follow-up. Five infectious complications were observed, including three varicella-zoster virus (VZV) infections.


In our pediatric patients with LN, therapy with RTX + MMF combined with a rapid decrease in steroid appears to have been an efficacious treatment for severe LN but was associated with high rate of VZV infection. The potential of RTX to allow complete steroid avoidance warrants further investigation in children.


Lupus nephritis Children Rituximab Steroid minimization 


Compliance with ethical standards

The study protocol was approved by the Ethics committees of the participating institutions.


None to report.


  1. 1.
    Mackie FE, Kainer G, Adib N, Boros C, Elliott EJ, Fahy R, Munro J, Murray K, Rosenberg A, Wainstein B, Ziegler JB, Singh-Grewal D (2015) The national incidence and clinical picture of SLE in children in Australia—a report from the Australian Paediatric surveillance unit. Lupus 24:66–73CrossRefPubMedGoogle Scholar
  2. 2.
    Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228CrossRefPubMedGoogle Scholar
  3. 3.
    Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886–1895CrossRefPubMedGoogle Scholar
  4. 4.
    Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243–247CrossRefPubMedGoogle Scholar
  5. 5.
    Sundel R, Solomons N, Lisk L (2012) Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 21:1433–1443CrossRefPubMedGoogle Scholar
  6. 6.
    Quinlan C, Marks SD, Tullus K (2016) Why are kids with lupus at an increased risk of cardiovascular disease? Pediatr Nephrol 31:861–883CrossRefPubMedGoogle Scholar
  7. 7.
    Sozeri B, Deveci M, Dincel N, Mir S (2013) The early cardiovascular changes in pediatric patients with systemic lupus erythematosus. Pediatr Nephrol 28:471–476CrossRefPubMedGoogle Scholar
  8. 8.
    Quinlan C, Kari J, Pilkington C, Deanfield J, Shroff R, Marks SD, Tullus K (2015) The vascular phenotype of children with systemic lupus erythematosus. Pediatr Nephrol 30:1307–1316CrossRefPubMedGoogle Scholar
  9. 9.
    Alsufyani KA, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Nadel H, Malleson PN (2005) Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 32:729–733PubMedGoogle Scholar
  10. 10.
    Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168–3174CrossRefPubMedGoogle Scholar
  11. 11.
    Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G (2008) Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23:413–419CrossRefPubMedGoogle Scholar
  12. 12.
    Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G (2011) Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 6:2192–2199CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64:1215–1226CrossRefPubMedGoogle Scholar
  14. 14.
    Weidenbusch M, Rommele C, Schrottle A, Anders HJ (2013) Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 28:106–111CrossRefPubMedGoogle Scholar
  15. 15.
    Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L, Cairns T (2009) Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24:3717–3723CrossRefPubMedGoogle Scholar
  16. 16.
    Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72:1280–1286CrossRefPubMedGoogle Scholar
  17. 17.
    Pottel H (2017) Measuring and estimating glomerular filtration rate in children. Pediatr Nephrol 32:249–263CrossRefPubMedGoogle Scholar
  18. 18.
    Ruggiero B, Vivarelli M, Gianviti A, Benetti E, Peruzzi L, Barbano G, Corona F, Ventura G, Pecoraro C, Murer L, Ghiggeri GM, Pennesi M, Edefonti A, Coppo R, Emma F (2013) Lupus nephritis in children and adolescents: results of the Italian collaborative study. Nephrol Dial Transplant 28:1487–1496CrossRefPubMedGoogle Scholar
  19. 19.
    Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT (2012) Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nikpour M, Urowitz MB, Ibanez D, Harvey PJ, Gladman DD (2011) Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther 13:R156CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Zhang H, Zheng Y, Liu L, Fu Q, Li J, Huang Q, Liu H, Deng R, Wang C (2016) Steroid avoidance or withdrawal regimens in Paediatric kidney transplantation: a meta-analysis of randomised controlled trials. PLoS One 11:e0146523CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Masood S, Jayne D, Karim Y (2009) Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus 18:106–115CrossRefPubMedGoogle Scholar
  23. 23.
    Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS (1999) Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 68:158–161CrossRefPubMedGoogle Scholar
  24. 24.
    Okamoto A, Abe A, Okamoto M, Kobayashi T, Inaguma Y, Tokuda M, Yanada M, Morishima S, Kanie T, Yamamoto Y, Tsuzuki M, Mizuta S, Akatsuka Y, Yatsuya H, Yoshikawa T, Emi N (2014) A varicella outbreak in B-cell lymphoma patients receiving rituximab-containing chemotherapy. J Infect Chemother 20:774–777CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2017

Authors and Affiliations

  • Julien Hogan
    • 1
    Email author
  • Astrid Godron
    • 2
  • Véronique Baudouin
    • 1
  • Theresa Kwon
    • 1
  • Jérôme Harambat
    • 2
  • Georges Deschênes
    • 1
  • Olivier Niel
    • 1
  1. 1.Pediatric Nephrology Department, Robert Debré Hospital Assistance publique–Hôpitaux de Paris (APHP)ParisFrance
  2. 2.Pediatric Nephrology UnitPellegrin-Enfants Hospital–Bordeaux UniversityBordeauxFrance

Personalised recommendations